AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02073500 — intervention group
Intervention type: OTHER
Intervention: Observational study.
Description: Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease.
Study NCT06294249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-induced Incision
Description: On the treatment side, an incision was made on the crest of the alveolar soft tissue using the laser.
Study NCT06294249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punch Incision
Description: On the control side, a punch incision was made on the crest of the alveolar soft tissue using using a punch.
Study NCT06294249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant Placement
Description: Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
Study NCT06294249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Placement
Description: Implant placement was done in both laser and punch arms. The drilling was performed based on the company (Straumman) protocol. On each side, a dental implant (Straumman SP, Basel, Switzerland) and healing abutment were placed. Patients were visited at 24, 48, 72 hours, and 7 days after insertion.
Study NCT04504721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light therapy
Description: The intervention will take 8 weeks with 30 minutes exposure at awakening to blue-enriched white light.
Study NCT04111510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes (TIL) LN-145
Description: The TIL autologous therapy with LN-145 is comprised of the following steps:~1. Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~2. LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~3. A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~4. Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~5. Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization).
Study NCT03350958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Bread
Description: 100g standard White Bread (control), toasted with 20g of butter.
Study NCT03350958 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Bread
Description: 100g standard White Bread (control), toasted with 20g of butter.
Study NCT03653650 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP plus BCL
Description: Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
Study NCT03653650 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BCL plus PFL
Description: Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
Study NCT03653650 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch plus ocular lubricant ointment
Description: Eye patch plus ocular lubricant ointment every 24 hours.
Study NCT04324996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
Description: The CAR-NK cells are universal off the shelf NK cells enriched from umbilical cord blood and engineered genetically.
Study NCT05031091 — intervention group
Intervention type: OTHER
Intervention: standardised exposure questionnaire
Description: A standardised exposure questionnaire will be conducted face to face or by telephone. The search for risk factors for leprosy and in particular direct or indirect contact with armadillos will be explored
Study NCT01180894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: 100 mg IV TIW
Study NCT01180894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02539173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound scan
Description: Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes.
Study NCT03501004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile acupuncture needles for single use
Description: Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
Study NCT03501004 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sterile acupuncture needles for single use
Description: Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm\*25mm.
Study NCT03803670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: evaluation of cerebrospinal fluid of ALL
Description: We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
Study NCT02531425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IT-pIL12-EP
Description: Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
Study NCT04088240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DPA enriched n-3
Description: 4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)
Study NCT04088240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 control
Description: 4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)
Study NCT04088240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 g/d placebo control (light olive oil)
Study NCT03504540 — intervention group
Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood test for complement factors and genetic polymorphisms of AMD analysis
Study NCT03969056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) Activity
Description: The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
Study NCT03969056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10,000 steps
Description: The intervention provides participants with an automated daily 10,000 step goal intervention
Study NCT01818739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node detection
Description: Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
Study NCT01818739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
Study NCT01818739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isosulfan blue
Description: Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
Study NCT01818739 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy
Description: Undergo sentinel lymph node biopsy
Study NCT04640558 — intervention group
Intervention type: DEVICE
Intervention: Muscle strength measurement
Description: The bilateral gluteus medius muscle strength of each participant will be measured by the assessor (MB) blinded to the participants using the Lafayette manual muscle tester. (Lafayette Instrument Company, Lafayette IN, USA). In the participant's side-lying position, the practitioner applied resistance from the upper ankle to the abduction movement with slight flexion of the upper hip. During the measurements, the participants were asked to perform the maximum isometric contraction for 3 seconds. Gluteus medius muscle strength measurements were repeated three times, one minute apart, on the right and left sides. The mean of the measurements was calculated and recorded
Study NCT04155086 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
Description: The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Study NCT04155086 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis
Description: The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
Study NCT01781650 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation method.
Description: Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
Study NCT01781650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion method.
Description: Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
Study NCT01781650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange method.
Description: Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
Study NCT00139542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One shock per minute AED protocol
Description: Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
Study NCT00139542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines 2000 AED protocol
Description: Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
Study NCT04138914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal Cryotherapy
Description: Ablation of the cancer focus within the prostate using cryotherapy
Study NCT02276352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 1
Study NCT02276352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment 2
Study NCT02276352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment 3
Study NCT01595230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closing the mesenteric defects with clips during opration
Description: The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
Study NCT02901054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: A single 15-min intravenous infusion of ondansetron
Study NCT03802305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computerized intraosseous technique (Quicksleeper™)
Description: The anesthetic solution is administered with a specific equipment allowing the injection step by step:~* anesthesia of the interdental papilla,~* positioning of the needle and perforating of the interdental space,~* Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment.
Study NCT03802305 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: loco-regional anesthesia (IANB technique)
Description: The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
Study NCT04587414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth +counselling contacts
Description: The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. The eHealth intervention is complemented by face-to-face and telephone counselling on physical activity which comprises 4 to 6 contacts between a health care professional and the patient as well as at least 3 telephone contacts during 6 months.
Study NCT04587414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth
Description: The 6 month eHealth intervention comprises continuous self-monitoring of PA and SB using hip-worn accelerometer and ExSed application, which gives cloud-computed personal feedback about accelerometer-measured PA and SB on smartphone and provides a platform for a health care professional to set and monitor patient's personal activity goals as well as give personalized feedback to the patient. In addition, instructions and video-demonstrations on how to reach the goals are provided via Internet. No telephone calls nor face-to-face counselling contacts on physical activity are taken.
Study NCT04587414 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Usual care and councelling given to type 2 diabetics within the primary health care setting.
Study NCT04587414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care and councelling given to type 2 diabetics within the primary health care setting.
Study NCT01407471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol + Spironolactone
Description: One application 6 days a week during 4 weeks
Study NCT01407471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol + Placebo
Description: One application 6 days a week during 4 weeks
Study NCT01407471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + Spironolactone
Description: One application 6 days a week during 7 weeks
Study NCT01407471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Placebo
Description: One application 6 days a week during 7 weeks
Study NCT00948233 — intervention group
Intervention type: BEHAVIORAL
Intervention: Video Game
Description: Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
Study NCT00948233 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pamphlet
Description: Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
Study NCT00948233 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Computer surveys taken at 4 points throughout the study.
Study NCT02483156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg
Description: The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
Study NCT02483156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir tablet (SOF) 400 mg - once daily
Description: SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
Study NCT02483156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening
Description: RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
Study NCT02585024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Study NCT01551576 — intervention group
Intervention type: DEVICE
Intervention: Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe
Description: Hand held transrectal Combined Ultrasound and photoacoustic imaging (PAI) probe. PAI is a non-ionizing imaging technique
Study NCT04491019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise group
Description: Balance exercises will be carried out with a physiotherapist
Study NCT01004731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with Carboplatin/Gemcitabine
Description: A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
Study NCT01381276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-Carotene bio-fortified cassava porridge without oil
Description: 300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
Study NCT01381276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-Carotene bio-fortified cassava porridge with oil
Description: 300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
Study NCT01381276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White cassava porridge with retinyl palmitate reference dose
Description: 300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
Study NCT01367418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia (PCA)
Description: Morphine 1 mg/ml
Study NCT01367418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Description: Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
Study NCT04669938 — intervention group
Intervention type: OTHER
Intervention: oropharyngeal and intestinal microbiota
Description: analysis of oropharyngeal and intestinal microbiota
Study NCT04669938 — intervention group
Intervention type: OTHER
Intervention: host genotype
Description: analysis of a part of host genotype
Study NCT04669938 — intervention group
Intervention type: OTHER
Intervention: host immune factors
Description: analysis of host immune factors
Study NCT04669938 — intervention group
Intervention type: OTHER
Intervention: viral sequence
Description: analysis of viral sequence
Study NCT00793559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terlipressin
Description: 1 mg of terlipressin one time only
Study NCT00793559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin
Description: 1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
Study NCT02649218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: QGE031 240 mg s.c. q4w
Study NCT01451931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-care Ultrasound
Description: Perform ultrasonography in the ED (physician).
Study NCT01451931 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiology Ultrasound
Description: Diagnostic ultrasound completed in the radiology department at time 0.
Study NCT01451931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology CT
Description: Computed tomography of abdomen completed in the radiology department at time 0.
Study NCT01328834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Sustained-release Capsules (ADVAGRAF)
Description: Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
Study NCT02737189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy
Description: Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration